HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Growing incidence of Merkel cell carcinoma draws researchers’ attention
-
- Is neoadjuvant immunotherapy the best treatment approach for regionally advanced Merkel cell carcinoma?
- Hey, government people, have you heard about mesothelioma? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- Primary palliative care education vital for APRNs to help meet ‘tremendous need’ Pam Malloy, MN, RN, FPCN, FAAN
- BRCA testing underutilized despite access, coverage
- ‘Smarter and stronger’ T cells offer hope for more effective, less toxic cancer therapy
- Research initiative aims to better understand link between immunotherapy, type 1 diabetes
- Phase 0 trials ‘quickest route’ for development of glioblastoma treatments
- Deep learning: Getting better information to clinicians faster, cheaper and more accurately
-
- Supportive care measures underused among older patients with multiple myeloma
- New AUA guideline offers ‘relevant blueprint’ for testicular cancer diagnosis, treatment
- Patients lack understanding of genomic results in Lung-MAP study
- Nipple-sparing mastectomy complication rates decline despite expanding indications
- Ipilimumab-nivolumab combination safe for historically unstudied patients with lung cancer
- Subcutaneous daratumumab attains deep response in multiple myeloma
- Genetic factors influence breast cancer risk after radiotherapy for Hodgkin lymphoma
- Functional impairment linked to higher mortality among older adults with hematologic malignancies
-
- PD-L1 alterations identify T-cell inflamed diffuse large B-cell lymphoma
- BRCA2 mutation may predispose children to lymphoma
- CAR T-cell therapies may be cost-effective for patients with lymphoma subtype
- Venetoclax, obinutuzumab regimen appears safe, effective for chronic lymphocytic leukemia
- Venous thromboembolism risk factors common among postpartum women
- Next-generation hypomethylating agent shows promise for intermediate-, high-risk myelodysplastic syndrome
- Dabrafenib-trametinib combination confers durable survival benefit in BRAF-mutated metastatic melanoma
- E-cigarette use rises among patients with cancer
-
- National Lung Screening Trial follow-up confirms low-dose CT reduces lung cancer deaths
- Hurricane disaster declarations associated with shorter survival for patients receiving radiotherapy for lung cancer
- USPSTF upholds recommendation against screening for pancreatic cancer
- Erdafitinib appears effective for locally advanced, metastatic urothelial carcinoma
- Targeted therapies linked to modest survival benefit for elderly patients with renal cell carcinoma
- USPSTF: Screen women with increased risk for BRCA1, BRCA2 mutations
- Breast cancer metastasis risk remains elevated 10 years after childbirth
- ‘Tremendous racial and ethnic disparity’ observed in access to matched donor stem cells
-
- Previous hematologic malignancies increase risk for head and neck cancers
- Chemoradiotherapy fails to improve outcomes for advanced endometrial cancer
- Financial conflicts common, often undisclosed among authors of ASCO practice guidelines
- FDA approves Polivy regimen for diffuse large B-cell lymphoma
- FDA approves Revlimid-based regimen for previously treated follicular, marginal zone lymphoma
- FDA expands Darzalex approval for multiple myeloma
- FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma
- FDA grants priority review to tazemetostat for epithelioid sarcoma
-
- FDA grants breakthrough therapy designation to NKTR-214 in combination with Opdivo for advanced melanoma
- American Cancer Society names new chief medical, scientific officer
- Ovarian Cancer Research Alliance honors Roswell Park deputy director
- GO2 Foundation for Lung Cancer presents lectureship award
- NCI grant to fund research into aggressive pancreatic cancer subtype